Bausch Health Companies (TSE:BHC) Stock Price Down 0.7% – What’s Next?

Bausch Health Companies Inc. (TSE:BHC)’s share price was down 0.7% during mid-day trading on Friday. The stock traded as low as C$8.69 and last traded at C$9.03. 407,227 shares changed hands during trading, a decline of 24% from the average daily volume of 537,914 shares. The stock had previously closed at C$9.09.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised shares of Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 22nd. Three equities research analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, Bausch Health Companies has an average rating of “Hold”.

Bausch Health Companies Stock Down 0.7%

The company has a market cap of C$3.38 billion, a price-to-earnings ratio of -3.07, a price-to-earnings-growth ratio of 0.21 and a beta of 0.82. The stock’s fifty day moving average is C$8.66 and its two-hundred day moving average is C$7.86. The company has a debt-to-equity ratio of -1,173.29, a quick ratio of 0.58 and a current ratio of 1.44.

Bausch Health Companies (TSE:BHC) last announced its earnings results on Wednesday, July 29th. The company reported C$1.79 earnings per share (EPS) for the quarter. Bausch Health Companies had a positive return on equity of 87.57% and a negative net margin of 12.02%. The company had revenue of C$4.05 billion for the quarter. Sell-side analysts predict that Bausch Health Companies Inc. will post 5.55 earnings per share for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.